ASCO '19
Jun 06, 2019•18 min
Episode description
Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan.
*caveats apply
For the best experience, listen in Metacast app for iOS or Android
